艾美疫苗(06660.HK) 公布，预期截至2024年12月31日，将录得未经审核收入介乎12.5亿至13亿元人民币(下同)，较上一年度收入11.9亿元，增加6,000万至1.1亿元，增幅为5%至9%；未经审核净亏损介乎2.5亿至2.9亿元之间，较上一年度净亏损19.5亿元，大幅减亏16.6亿至17亿元，减亏幅度为85%至87%。
公告指，收入增加主要由于公司乙肝疫苗收入增加；至于综合净亏损减少主要由于本年度大额资产减值损失金额减少、收入增加。(js/w)
(港股报价延迟最少十五分钟。沽空资料截至 2025-03-14 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.